Z Temesgen

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Current status of antiretroviral therapies
    Z Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, Minnesota 55905, USA
    Expert Opin Pharmacother 2:1239-46. 2001
  2. ncbi request reprint [Bone and joint involvement in human immunodeficiency virus infection]
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Acta Chir Orthop Traumatol Cech 72:177-82. 2005
  3. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
  4. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
  5. ncbi request reprint Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008

Detail Information

Publications5

  1. ncbi request reprint Current status of antiretroviral therapies
    Z Temesgen
    Mayo Clinic and Foundation, Division of Infectious Diseases, Rochester, Minnesota 55905, USA
    Expert Opin Pharmacother 2:1239-46. 2001
    ..Currently, there are 15 FDA-approved antiretrovirals categorised into three classes of drugs. Several others are in various stages of basic and clinical development...
  2. ncbi request reprint [Bone and joint involvement in human immunodeficiency virus infection]
    Z Temesgen
    Division of Infectious Diseases, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Acta Chir Orthop Traumatol Cech 72:177-82. 2005
    ..This article attempts to provide a broad overview of the complications of HIV and its treatment involving the bone and joints...
  3. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  4. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  5. ncbi request reprint Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008
    ..Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy...